Since 1993, the AACR has awarded more than $542 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
The survival rate for nearly half of children diagnosed with high-risk neuroblastoma remains tragically low. This devastating outcome is often linked to the amplification of the MYCN gene. Dr. Daniel Harki, recipient of two AACR-Bayer Innovation and Discovery (IND) Grants.
The AACR Annual Meeting 2025 will welcome the global cancer community to the McCormick Place Convention Center in Chicago on April 25-30. We are thrilled to announce the AACR grantees selected to present their work in oral and poster presentations and are extremely proud and excited about the progress they have made with support from the AACR and its funding partners!
2025 AACR Annual Meeting attendees are invited to join the Meet the Research Grant Reviewers session held on Monday, April 28, 2025. Attendees will have the opportunity to engage with AACR research grant reviewers James M. Cleary, MD, PhD, and Sandra W. Ryeom, PhD, on all grant review topics. Continue reading to get a sneak peek of what you can expect from this interactive session.
Ovarian tumors are often resistant to traditional chemotherapy and immunotherapy. Supported by a 2022 AACR-Bristol Myers Squibb Immuno-oncology Research Fellowship, Dr. Sung-Min Hwang has uncovered a novel strategy for reinvigorating the ability of dysfunctional intratumoral T cells to combat cancer.
2023 AACR-St. Baldrick's Foundation Pediatric Cancer Research Grant recipient, Alanna Church, MD, shared how being an AACR grantee has advanced her work in improving molecular tumor profiling in the diagnosis and treatment of children with cancer.
ER+ breast cancer patients typically receive endocrine therapies targeting the estrogen receptor, but approximately half of high-grade diseases will likely progress, highlighting the urgent need for new and effective treatment options. Supported by a 2018 AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship, Dr. Sicong Zhang, investigated why BET inhibitors (BETi), a promising class of anti-cancer drugs, have failed to show efficacy in clinical trials for ER+ breast cancer patients.
Having received two AACR research grants at critical points in her career, Eunyoung Choi, PhD, shared the impact of these grants as she progressed through the academic ranks to become an associate professor.
We are extremely proud of our past and present grantees who presented and published their findings throughout 2024. Their accomplishments have been made possible, thanks to the support of the AACR and its funding partners. JANUARY Tumor development in...
Supported by a 2016 AACR-QuadW Foundation Sarcoma Research Fellowship, Joanna Przybyl, PhD, showed how ctDNA levels correlated with treatment response in leiomyosarcoma, a rare cancer, and uncovered the potential utility of this liquid biopsy approach to other sarcomas.
Despite the surge in new treatments, multiple myeloma remains stubbornly incurable. Patients typically respond to their first treatment for about two years, but subsequent therapies often provide diminishing relief due to overlapping mechanisms of action. This underscores the urgent need for novel therapeutic strategies rather than mere variations of existing ones. Amin Sobh, PhD, recipient of the 2019 AACR-Takeda Oncology Myeloma Research Fellowship, identified adenylate kinase 2 as a promising target, particularly for multiple myeloma patients with the t(4;14) chromosomal translocation.